Article info
Short report
Oral water-soluble contrast (Gastrografin) for malignant bowel obstruction: open label pilot study
- Correspondence to Karyn Foster, Palliative and Supportive Care, Mater Misericordiae Ltd, South Brisbane, Queensland, Australia; karyn.foster{at}mater.org.au
Citation
Oral water-soluble contrast (Gastrografin) for malignant bowel obstruction: open label pilot study
Publication history
- Received October 26, 2021
- Accepted December 27, 2021
- First published January 19, 2022.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.